1. 1) Stupp R, Mason WP, van den Bent MJ, et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987–996.
2. 2) Stupp R, Hegi ME, Mason WP, et al. European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459–466.
3. 3) Wakabayashi T, Natsume A, Mizusawa J, et al. Members of Japan Clinical Oncology Group Brain Tumor Study Group (JCOG-BTSG): JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma. J Neurooncol 2018; 138: 627–636.
4. 4) Nakada M. Drug repositioning in neuro-oncology. Progress in Neuro-Oncology 2017; 23: 1–8.
5. 5) Yoshino A, Ogino A, Yachi K, et al. Effect of IFN-beta on human glioma cell lines with temozolomide resistance. Int J Oncol 2009; 35: 139–148.